Erbitux - Enhanced Efficacy Demonstrated In Patients With KRAS Wild-Type Tumors In First Line Metastatic Colorectal ... (Medical News Today)

New analyses of two randomized, controlled clinical trials investigating Erbitux® (cetuximab) in the treatment of 1st-line metastatic colorectal cancer (mCRC) highlight the increased efficacy of Erbitux in patients with "normal," non-mutated or so-called tumors with wild-type KRAS.